Published in Gene Therapy Weekly, March 23rd, 2006
The agreement provides for the transfer of Geron's vaccine production process to Cambrex and the current good manufacturing practices (cGMP) manufacture of GRNVAC1 by Cambrex.
GRNVAC1 is a therapeutic cancer vaccine comprised of autologous dendritic cells loaded ex vivo with telomerase mRNA. In March 2005, results of the first completed phase I-II clinical trial of GRNVAC1 in metastatic prostate cancer patients was published in the Journal of Immunology (JI,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.